CNS Drugs

Papers
(The TQCC of CNS Drugs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond160
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment115
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies92
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status92
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview81
Intranasal Insulin for Alzheimer’s Disease79
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies67
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia65
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability61
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome61
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression59
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis58
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability54
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication54
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys53
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain52
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis52
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score51
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders49
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies46
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis43
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study41
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis39
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs38
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis38
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)38
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status37
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia36
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders35
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update33
Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment32
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder31
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review31
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment31
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies31
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)31
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy30
Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke30
Pharmacotherapy to Manage Central Post-Stroke Pain29
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis28
Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures27
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience27
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder27
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies26
Dextromethorphan/Bupropion: First Approval25
Risdiplam: A Review in Spinal Muscular Atrophy25
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively25
Potential Role of Curcumin for the Treatment of Major Depressive Disorder25
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study24
COMT Inhibitors in the Management of Parkinson’s Disease24
Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases22
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis22
Nusinersen: A Review in 5q Spinal Muscular Atrophy21
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data21
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System20
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants20
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis20
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?20
Treatment Options in Refractory Autoimmune Encephalitis20
Opicapone: A Review in Parkinson’s Disease19
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment19
Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage19
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations19
Pharmacological Management of Apathy in Dementia19
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention19
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden18
A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD)18
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study18
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing18
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program18
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis18
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval17
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)17
Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials17
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine17
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial17
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders16
New Oral Drugs for Migraine15
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation15
Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study15
Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)14
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development14
Efficacy and Safety of Ibuprofen Plus Paracetamol in a Fixed-Dose Combination for Acute Postoperative Pain in Adults: Meta-Analysis and a Trial Sequential Analysis14
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use14
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis14
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia14
Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study14
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives14
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease14
0.14494299888611